Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

TEVA

Phase 3

TEV-‘749 (olanzapine) [Subcutaneous Long-Acting Injectable]

Schizophrenia

H1 2025

SOLARIS w/ Medincell: 5/8/24 Positive Ph3 efficacy results. 9/23/24- Data from Ph3 Period 1 presented at ECNP. Period 2 with safety data topline readout in the H1 2025. Presents at Psych Congress '24.

Data readout

GUTS

Phase 1

Revita

Obesity and type 2 diabetes

Q2 2025

REMAIN -1: 11/4/24 Open label data from REVEAL-1 cohort of REMAIN-1 in Q4 2024 & anticipates a mid-point data analysis of the REMAIN-1 cohort in Q2 2025. 1/13/25- Initial clinical results; mid-point data analysis expected in Q2 2025.

Data readout

INSM

Phase 2b

TPIP (Treprostinil Palmitil Inhalation Powder)

PAH (Pulmonary arterial hypertension)

Mid-2025

Enrolling in Ph2 study in PAH. DSMB completed & recommended to continue study. 10/26/23- Reported interim data. 5/9/24 Encouraging blinded data reported & topline results in mid-2025.

Data readout

ACRS

Phase 2b

Bosakitug (ATI-045)

Atopic Dermatitis (AD)

H1 2025

2/27/25- Initiation of enrollment in Ph2b on track for H1 2025.

Initiation

KRYS

Phase 1

KB407

Cystic Fibrosis

Mid-2025

CORAL-1/US study. 01/2024- Initiated dosing in Cohort 2. 8/5/24- Initiate third and final cohort in H2 2024. 12/12/24- safe and well tolerated at all dosing regimens. 2/19/25- Interim data for Cohort 3 in mid-2025.

Additional data readout

EXEL

Phase 1b/2

Zanzalintinib +/- atezolizumab

Advanced or metastatic solid tumors- Clear Cell Renal Carcinoma (ccRCC)

H1 2025

STELLAR-001 trial: 1/25/25- Reported results from expansion cohort of Ph1b/2 at ASCO GI '25. Trial shows enhanced progression-free and overall survival. 2/11/25- Additional data in H1 2025.

Additional data readout

JSPR

Phase 1b/2a

Briquilimab

Chronic Inducible Urticaria

H1 2025

SPOTLIGHT study. 10/14/24- Announced positive prelim data. To present full data in H1 2025.

Data readout

RLYB

Phase 2

RLYB212

FNAIT (Fetal and Neonatal Alloimmune Thrombocytopenia)

Q2 2025

2/6/24- Update on Ph2 discussions w/ EMA in H1 2024. 10/29/30- Ph2 CTAs approved. 2/11/25- Initiates Ph2 dosing. 3/13/25- Report data in Q2 and Q3 2025.

Data readout

TRVI

Phase 2b

Haduvio (oral nalbuphine ER)

Idiopathic Pulmonary Fibrosis

H1 2025

CORAL Trial. 2/25/25- completed enrollment in its Phase 2b CORAL trial.

Data readout

ACRS

Phase 2

Bosakitug (ATI-045)

Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

H1 2025

2/27/25- Data in Chinese patients expected in H1 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20